Search Results
Dec 23, 2025, 10:00 ET SHAKE UP THE SELTZER AISLE: SWRL LAUNCHES AMERICA'S FIRST ZERO-SUGAR, 89-CALORIE "MAKGEOLLI SELTZER"
point, offering a new category rooted in fermentation and rice.In the glass—or rather, the can—SWRL delivers a mouthfeel closer to a pet-nat (pétillant naturel) wine than a standard seltzer. Once swirled, the rice sediment blends into a creamy, silky fizz with a gentle tang, reminiscent of
More news about: SWRL
Dec 19, 2025, 07:56 ET The Scarcity Premium: Investors Target High-Grade Systems in a $4,300 Market
approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions
More news about: Equity Insider
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
MIBC.iv Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017 Apr;14(4):221-234. doi: 10.1038/nrclinonc.2016.188. Epub 2016 Nov 22. PMID: 27874062; PMCID: PMC6054138.v
More news about: Astellas Pharma Inc.
Dec 15, 2025, 12:04 ET Africa Emerges as Gold's Next Supply Engine Amid Record Prices and Development Wave
approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions
More news about: USA News Group
Dec 14, 2025, 19:22 ET Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
2011;2011:601953[2] iPSC = induced pluripotent stem cell.[3] MSC = mesenchymal stem (or stromal) cell.[4] Bloor AJC, et al. Nat Med. 2020;26:1720–1725[5] Kelly K, et al. Nat Med. 2024;30:1556–1558[6] Orphan Drug Designation qualifies Cynata for incentives including extended marketing exclusivity,
More news about: Cynata Therapeutics
Dec 12, 2025, 08:12 ET Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
here.ReferencesSmith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón,
More news about: Swedish Orphan Biovitrum AB
Dec 11, 2025, 10:06 ET ASCAP UNWRAPS 2025 NEW CLASSIC HOLIDAY TOP 10 WITH HITS FROM MARIAH CAREY, KELLY CLARKSON, JUSTIN BIEBER, KATY PERRY, JIMMY FALLON, MEGHAN TRAINOR AND MORE
(1970)"Here Comes Santa Claus (Down Santa Claus Lane)" by Gene Autry and Oakley Haldeman (1947)"Deck the Halls" (Nat King Cole version), arranged by Nat King Cole and Leland Gillette (1960)"This Christmas" by Donny Hathaway and Nadine McKinnor (1970)"Santa Baby" by
More news about: ASCAP - American Society of Composers, Authors and Publishers
Dec 10, 2025, 18:30 ET Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
2023;401(10389):1655-1668.2 Shah MA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.3 Lee, JK et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes
More news about: Astellas Pharma Inc.
Dec 09, 2025, 11:19 ET Journal of Cardiac Failure December Issue Showcases Innovations in Transplant Care, Digital Therapeutics, and Global Heart Failure Treatment Strategies
Approaches to Hepatitis C Treatment Protocols in Heart TransplantationWith heart transplantation from hepatitis C–positive (HCV NAT–positive) donors increasing, clinicians face wide variation in how best to manage these recipients—ranging from prophylactic antiviral therapy to treatment
More news about: Heart Failure Society of America
Dec 06, 2025, 12:28 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Scheffer IE, et al. Epilepsia. 2025;00:1-10Gallop K, et al. Epilepsy Behav. 2021;124:10824 Scheffer IE et al. Nat Rev Dis Primers 2024;10:61 Surdi P, et al. Epilepsia. 2024;65(11):3279-3292 Samanta D, et al. Epilepsy Behav. 2025;170:110472 Dlugos
More news about: H. Lundbeck A/S
Dec 06, 2025, 12:25 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Scheffer IE, et al. Epilepsia. 2025;00:1-10Gallop K, et al. Epilepsy Behav. 2021;124:10824 Scheffer IE et al. Nat Rev Dis Primers 2024;10:61 Surdi P, et al. Epilepsia. 2024;65(11):3279-3292 Samanta D, et al. Epilepsy Behav. 2025;170:110472 Dlugos
More news about: H. Lundbeck A/S
Dec 04, 2025, 15:17 ET AlidaBio Introduces the EpiPlex™ Duo-Mod™ Service for Concurrent m6A and Inosine Mapping with Integrated RNA Expression Profiling
the translational potential of RNA modifications. For example, in a recent comprehensive survey of 162 localized primary prostate tumors, Xin Xu et al (Nat Genet. 2025 Apr;57(4):934-948) showed that global and locus-specific m6A patterns strongly correlate with tumor aggression, progression risk, and patient
More news about: Alida Biosciences
Dec 04, 2025, 07:00 ET VyOS Networks Announces Support for Red Hat OpenShift Virtualization
replaces hardware routers with virtualized, cost-efficient alternatives, and enables consistent, policy-based traffic control through VyOS's advanced QoS, NAT, and firewall features.Achieving validation for VyOS Universal Router on Red Hat OpenShift Virtualization underscores our commitment to delivering
More news about: VyOS Networks Corporation
Dec 04, 2025, 07:00 ET Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America
optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers. Nat Commun. 2025a;16(1):456. Published 2025 Jan 7. doi:10.1038/s41467-025-55843-9.Maine CJ, Picarda G, Miyake-Stoner SJ, et
More news about: Replicate Bioscience
Dec 04, 2025, 02:39 ET The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN
here.References Data on file using literature consensus. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. Servais A, et al. Kidney Int. 2012;82(4):454-464. Zand L, et al. J Am Soc Nephrol.
More news about: Swedish Orphan Biovitrum AB
Dec 03, 2025, 18:10 ET Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
2021;26(10):5481-5503.Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying
More news about: Eisai Inc.
Dec 02, 2025, 16:40 ET New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
2021;26(10):5481-5503.Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12:3451. doi: 10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying
More news about: Eisai Inc.
Dec 01, 2025, 19:35 ET Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Alzheimers Dis 2025; 1 (12), 13.Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease. Nat Med. 31, 2044–2053 (2025).
More news about: Eisai Inc.
Dec 01, 2025, 06:19 ET Tianlong fortalece a segurança das transfusões com soluções inovadoras de triagem sanguínea no Dia Mundial da AIDS 2025
anti-gotejamento, oferecendo biossegurança robusta em ambientes laboratoriais exigentes.Reagentes NAT de alta sensibilidade para detectar infecções de baixa carga viralO reagente NAT de alta sensibilidade da KHB complementa a plataforma automatizada da Tianlong, utilizando PCR em tempo
More news about: Tianlong Science and Technology
Dec 01, 2025, 06:09 ET Tianlong refuerza la seguridad de las transfusiones con soluciones innovadoras para el análisis de sangre en el Día Mundial del SIDA 2025
que proporciona una bioseguridad sólida en entornos de laboratorio exigentes.Reactivos para NAT de alta sensibilidad para detectar infecciones de carga bajaEl reactivo para NAT de alta sensibilidad de KHB complementa la plataforma automatizada de Tianlong, que utiliza PCR cualitativa
More news about: Tianlong Science and Technology
Nov 29, 2025, 10:19 ET 텐룽, 2025 세계 에이즈의 날에 혁신적 혈액 검사 솔루션 공개...수혈 안전 강화에 일익
안정적으로 발휘되도록 작업 구역이 서로 독립되어 있고 HEPA 여과, UV 소독, 공기 흐름 제어, 드립 방지 기능도 갖췄다. 따라서 까다로운 실험실 환경에서도 완건한 생물학적 안전성을 제공한다.저부하 감염을 탐지하는 고감도 NAT 시약KHB의 고감도 NAT 시약은 추출과 증폭이 모두 가능한 올인원 형식으로 정성적 실시간 PCR로 텐룽의 자동 플랫폼을 보완한다.이 시약 시스템은 저바이러스 부하에서도 HBV와 HCV, HIV-1, HIV-2를 검출할 수 있다. 따라서 실험실에서는 창기 감염을
More news about: Tianlong Science and Technology
Nov 28, 2025, 11:29 ET Tianlong renforce la sécurité transfusionnelle grâce à des solutions innovantes de dépistage sanguin à l'occasion de la Journée mondiale de lutte contre le sida 2025
anti-goutte, offrant une biosécurité solide dans les environnements de laboratoire exigeants.Réactifs NAT à haute sensibilité pour détecter les infections à faible chargeLe réactif NAT à haute sensibilité de KHB complète la plateforme automatisée de Tianlong, qui utilise la PCR qualitative
More news about: Tianlong Science and Technology
Nov 28, 2025, 11:20 ET Tianlong stärkt die Transfusionssicherheit mit innovativen Blutuntersuchungslösungen am Welt-Aids-Tag 2025
robuste Biosicherheit in anspruchsvollen Laborumgebungen gewährleistet ist.Hochempfindliche NAT-Reagenzien zum Nachweis von Infektionen mit geringer ViruslastDas hochempfindliche NAT-Reagenz von KHB ergänzt die automatisierte Plattform von Tianlong und verwendet qualitative Echtzeit-PCR
More news about: Tianlong Science and Technology
Nov 28, 2025, 10:10 ET Tianlong refuerza la seguridad de las transfusiones en el Día Mundial del SIDA 2025
antigoteo, lo que proporciona una bioseguridad robusta en entornos de laboratorio exigentes.Reactivos NAT de alta sensibilidad para detectar infecciones de baja cargaEl reactivo NAT de alta sensibilidad de KHB complementa la plataforma automatizada de Tianlong, utilizando PCR cualitativa
More news about: Tianlong Science and Technology
Nov 28, 2025, 05:53 ET Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025
anti-drip design, delivering robust biosafety in demanding laboratory environments.High-Sensitivity NAT Reagents to Detect Low-Load InfectionsKHB's high-sensitivity NAT reagent complements Tianlong's automated platform, using qualitative real-time PCR in an all-in-one format that
More news about: Tianlong Science and Technology